Tuesday, October 20, 2015 3:57:09 PM
http://seekingalpha.com/pr/15023206-hemispherx-biopharma-europe-n-v-s-a-receives-positive-opinion-on-application-for-orphan-designation-by-the-european-medicines-agency-for-alferon-n-injection-to-treat-patients-with-middle-east-respiratory-syndrome-mers
The Market appears to have viewed it is a bit of a positive,.... but no great shakes.
“The two most powerful warriors are patience and time.”
- Leo Nikolaevich Tolstoy
Recent HEB News
- TMX Group Equity Financing Statistics - April 2023 • PR Newswire (Canada) • 05/08/2023 01:00:00 PM
- Statistiques de financement par actions du Groupe TMX pour avril 2023 • PR Newswire (Canada) • 05/08/2023 01:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM